Edition:
United States

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

12.88USD
3:59pm EST
Change (% chg)

$-1.64 (-11.29%)
Prev Close
$14.52
Open
$14.49
Day's High
$14.49
Day's Low
$12.81
Volume
35,075
Avg. Vol
--
52-wk High
$15.40
52-wk Low
$12.55

Chart for

About

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The... (more)

Overall

Beta: --
Market Cap(Mil.): $715.21
Shares Outstanding(Mil.): 49.26
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.83 15.71
EPS (TTM): -- -- --
ROI: -- 15.03 31.93
ROE: -- 16.54 16.16

BRIEF-Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc

* Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing Source text (http://bit.ly/2jcJaxu) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Nov 21 2017

Earnings vs. Estimates